[{"data":1,"prerenderedAt":182},["ShallowReactive",2],{"media-slots-en":3,"guide-item-en-hsct-conditioning":61},{"about.hero":4,"about.video":6,"about.video-cover":8,"charity.hero":10,"contact.hero":12,"evidence.hero":14,"footer.qr-blood":16,"footer.qr-mini":18,"footer.qr-official":20,"footer.qr-solid":22,"guide.hero":24,"home.hero":26,"home.news-featured":28,"home.story-featured":30,"news.hero":32,"news.lead":34,"news.thumb":36,"stories.cover":41,"stories.hero":48,"stories.lead":50,"wiki.cat":52,"wiki.detail-hero":57,"wiki.hero":59},[5],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%B3%E4%BA%8E%E5%8D%9A%E5%8C%BB%E5%90%8C%E8%A1%8C_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[7],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_compressed.mp4",[9],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_frame1.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[11],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%AC%E7%9B%8A%E8%B5%84%E6%BA%90%E9%93%BE%E6%8E%A5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[13],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F08\u002Fbde8f2354d29ffca7dcfe395ef4711b2.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[15],"https:\u002F\u002Fwww.yyhmedical.com\u002Fimages\u002Fevidence\u002Fhero.jpg",[17],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-blood.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[19],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-mini.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[21],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-official.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[23],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-solid.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[25],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E7%96%BE%E7%97%85%E7%9F%A5%E8%AF%86%E5%BA%93_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[27],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E9%A6%96%E9%A1%B5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[29],"\u002Fimages\u002Fhome\u002Fnews-featured.jpg",[31],"\u002Fimages\u002Fhome\u002Fstory-featured.jpg",[33],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E5%8F%8B%E5%85%B3%E6%B3%A8_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[35],"\u002Fimages\u002Fnews\u002Flead.jpg",[37,38,39,40],"\u002Fimages\u002Fnews\u002Fn1.jpg","\u002Fimages\u002Fnews\u002Fn2.jpg","\u002Fimages\u002Fnews\u002Fn3.jpg","\u002Fimages\u002Fnews\u002Fn4.jpg",[42,43,44,45,46,47],"\u002Fimages\u002Fstories\u002Fs1.jpg","\u002Fimages\u002Fstories\u002Fs2.jpg","\u002Fimages\u002Fstories\u002Fs3.jpg","\u002Fimages\u002Fstories\u002Fs4.jpg","\u002Fimages\u002Fstories\u002Fs5.jpg","\u002Fimages\u002Fstories\u002Fs6.jpg",[49],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E8%80%85%E6%95%85%E4%BA%8B_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[51],"\u002Fimages\u002Fstories\u002Flead.jpg",[53,54,55,56],"\u002Fimages\u002Fwiki\u002Fcat-1.jpg","\u002Fimages\u002Fwiki\u002Fcat-2.jpg","\u002Fimages\u002Fwiki\u002Fcat-3.jpg","\u002Fimages\u002Fwiki\u002Fcat-4.jpg",[58],"\u002Fimages\u002Fwiki\u002Fdetail-hero.jpg",[60],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%8A%97%E7%99%8C%E7%99%BE%E7%A7%91_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",{"slug":62,"kind":63,"title":64,"summary":65,"cover":66,"contentHtml":67,"toc":68,"relatedQuestions":178,"ymyl":179,"hasAlternate":181,"updatedAt":87},"hsct-conditioning","manual","Hematopoietic Stem Cell Transplantation: Conditioning","Understand the purpose, types of regimens, selection principles, common adverse effects, and timing of transplantation related to conditioning before hematopoietic stem cell transplantation, and help patients and family members better understand and prepare for transplantation.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F10\u002F13f1f1eb6c089591065709df2cc2895b.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","",[69,88,106,124,142,160],{"key":70,"title":71,"html":72,"relatedQuestions":73,"hotSummary":86,"updatedAt":87},"purpose-of-hsct-conditioning","What Is the Purpose of Conditioning Before HSCT?","\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Overview: Hematopoietic stem cell transplantation (HSCT) is an important treatment for certain blood disorders. Before an allogeneic HSCT, patients generally receive a course of treatment known as conditioning. Conditioning is a key part of transplantation: it prepares the body for donor stem-cell engraftment and helps reduce the risk of disease relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What is HSCT conditioning?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">When people first hear the term “conditioning,” they may wonder why treatment is still needed before transplantation. Conditioning is an essential preparatory stage. It involves chemotherapy, radiation therapy or immunosuppressive treatment before donor stem cells are infused.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">An allogeneic transplant generally proceeds in stages: first, conditioning is given to reduce abnormal cells and suppress certain immune responses; then healthy donor stem cells are infused; over time, these cells can establish a new blood-forming and immune system. Conditioning therefore connects transplant preparation with blood-cell recovery and reconstitution.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why is conditioning needed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">To reduce remaining disease cells and the risk of relapse\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">In leukemia, myelodysplastic syndromes and other blood disorders, abnormal cells may still be present before transplantation. If they continue to grow afterward, the disease may return and compromise the transplant outcome. Chemotherapy or radiation included in conditioning can further reduce these remaining cells and may lower relapse risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">To create conditions for donor stem cells to engraft\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">In allogeneic HSCT, healthy donor stem cells are infused into the recipient. Once they reach the bone marrow, they must survive, multiply and gradually establish a new blood-forming system. The recipient's existing marrow environment may be affected by disease, and immune reactions may reject donor cells. Conditioning reduces abnormal blood-forming cells, limits rejection and helps create an environment in which donor cells can grow. One way to picture it is preparing the soil before planting new “blood-forming seeds.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">To suppress immune reactions and reduce graft rejection\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Because allogeneic cells come from another person, genetic differences may cause the recipient's immune system to recognize and reject them. Suppressing the recipient's immune response during conditioning helps donor cells engraft.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Does conditioning have to completely “empty” the bone marrow?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Not necessarily. Conditioning is classified by intensity into myeloablative, reduced-intensity and non-myeloablative regimens. For some younger, fitter patients, a more intensive approach may be selected to achieve greater disease control. For older patients, people with lower treatment tolerance or those with significant organ-function concerns, reduced-intensity or non-myeloablative conditioning may be chosen to limit treatment-related risk. Stronger is not automatically better; the regimen must fit the patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong>Is more intensive conditioning always more effective?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Patients sometimes assume that higher drug doses must destroy more disease cells and therefore be preferable. In reality, greater intensity may improve disease control but may also increase organ damage, infection and transplant-related complications. The transplant team balances expected benefit against safety, considering age, disease type, disease status before transplantation, previous treatment, and the function of major organs such as the heart, liver and kidneys.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What should patients pay attention to during conditioning?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">Infection prevention\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Conditioning can impair immune function and increase infection risk. Maintain personal hygiene, follow the team's infection-prevention instructions and report any changes in your condition promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">Treatment-related symptoms\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Nausea, vomiting, poor appetite, mouth or oral-mucosal discomfort and fatigue may occur. The clinical team can provide supportive treatment tailored to these symptoms.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">Nutrition\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Good nutrition can help patients get through transplantation. With guidance from the treating team and nutrition professionals, try to maintain adequate intake, monitor weight changes and adjust meals according to your condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 8px;\">\u003Cspan style=\"font-size: 15px;\">Conditioning serves three major purposes: reducing residual disease cells and post-transplant relapse risk; creating favorable conditions for donor stem-cell engraftment; and suppressing recipient immune reactions so that new blood-forming and immune systems can develop. The most intensive regimen is not necessarily the best. An individualized plan that considers disease features, physical condition and transplant risks is an important foundation for transplantation.\u003C\u002Fspan>\u003C\u002Fp>",[74,77,80,83],{"question":75,"answer":76},"Q1: Does needing conditioning mean my disease is more serious?","Not necessarily. Conditioning is a standard part of transplantation and does not mean the disease has suddenly worsened. Its purpose is to prepare for transplantation and improve the chances of donor-cell engraftment.",{"question":78,"answer":79},"Q2: Is conditioning the same as standard chemotherapy?","Not exactly. Conditioning may include chemotherapy, but it also suppresses recipient immune responses, reduces the risk of graft rejection and helps donor stem cells engraft.",{"question":81,"answer":82},"Q3: Does everyone undergoing HSCT need conditioning?","Most patients undergoing allogeneic HSCT require conditioning. The specific regimen depends on the disease, the patient's physical condition and the transplant approach.",{"question":84,"answer":85},"Q4: How soon after conditioning are stem cells infused?","The timing follows the transplant protocol. The team considers whether conditioning has been completed, the patient's condition and the readiness of the donor cells before scheduling the infusion.","Conditioning is an important step in transplantation therapy, aimed at preparing the environment for donor hematopoietic stem cell engraftment and reducing the risk of disease recurrence.","2026-10-10",{"key":89,"title":90,"html":91,"relatedQuestions":92,"hotSummary":105,"updatedAt":87},"types-of-hsct-conditioning","What Types of Conditioning Regimens Are Used Before HSCT?","\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Conditioning before HSCT is an important part of preparing for transplantation. Because patients differ in disease type, age, physical condition and transplant goals, they do not all receive the same regimen. The three main categories are myeloablative conditioning (MAC), reduced-intensity conditioning (RIC) and non-myeloablative conditioning (NMA). They differ in intensity, ability to control disease and safety. More intensive treatment does not necessarily produce better results.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why are different regimens needed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients often notice that the drugs and schedules used before transplantation differ from one person to another. HSCT is not a single fixed treatment. Younger and older patients may tolerate treatment differently; newly diagnosed and relapsed disease may carry different risks; and previous therapies may affect a person's physical reserve. The team must balance disease control with the risks of treatment and select a suitable regimen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What are the main types?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">Myeloablative conditioning\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">MAC is traditionally the more intensive approach. It uses relatively high-intensity chemotherapy or radiation to remove as many remaining disease cells as possible, suppress the recipient's existing blood-forming and immune systems and facilitate donor-cell engraftment. It may provide stronger disease control for selected patients with higher-risk disease who are otherwise fit. However, its greater intensity may cause more substantial adverse effects, including increased infection risk and strain on organ function. Tolerance must be assessed carefully.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Reduced-intensity conditioning\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">RIC uses less intensive treatment than MAC. It does not simply mean “doing less”; it aims to reduce the burden on the patient's body while still allowing donor cells to engraft. It is often considered for older patients, those with reduced physical reserve or those with concerns about organ function. For these patients, a more intensive regimen may pose excessive treatment-related risks, so a gentler but still therapeutically active approach may be appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Non-myeloablative conditioning\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">NMA is also referred to as low-intensity conditioning. It generally has less impact on the recipient's existing blood-forming system and relies more on suppression of immune reactions to allow donor stem cells to establish a new blood-forming system. It places particular emphasis on limiting treatment-related toxicity and may suit some older or less treatment-tolerant patients. Because its direct ability to eliminate disease cells is more limited, the patient's disease risk must also be considered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How do the three approaches compare?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The main difference is treatment intensity. MAC generally has stronger direct disease-cell elimination but imposes a greater physical burden. RIC seeks a balance between disease control and safety while reducing toxicity. NMA has lower intensity and emphasizes tolerance, but its disease-control role must be assessed together with other treatment mechanisms. No single regimen is best for every patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How does the team choose a regimen?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The decision considers several factors. First are disease characteristics: acute leukemia, myelodysplastic syndromes and other conditions have different risks and treatment goals. Second are patient factors, including age, overall health, heart and lung function, liver and kidney function and prior treatment. The transplant method, donor characteristics and disease status at transplantation also matter. The regimen is therefore determined through the transplant team's overall medical assessment rather than by the patient alone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Is stronger conditioning always better?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients may assume that a more intensive regimen removes disease more thoroughly and must improve transplant outcomes. That is not necessarily true. More intensive conditioning may improve disease control but can also increase infections, organ damage and transplant-related complications. If intensity exceeds what a patient can tolerate, it may adversely affect the subsequent transplant process. The aim is not maximum intensity but appropriate disease control within the patient's capacity to tolerate treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How can patients participate during conditioning?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Conditioning is an important phase of transplantation, and cooperation with the medical team matters. Prevent infections through personal hygiene and promptly report fever or signs of infection. Pay attention to nausea, poor appetite, mouth discomfort, fatigue or other changes; the team can provide symptom-directed supportive care. Maintain nutrition and adequate rest to help you complete the transplant process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">MAC, RIC and NMA differ in intensity, disease-control potential and safety. Choosing the strongest regimen is not automatically best. The team individualizes the approach according to disease characteristics, physical condition and transplant goals to support both safety and effectiveness.\u003C\u002Fspan>\u003C\u002Fp>",[93,96,99,102],{"question":94,"answer":95},"Q1: Does every HSCT patient receive the same conditioning regimen?","No. The regimen is tailored to age, disease type, physical condition, transplant method and disease risk.",{"question":97,"answer":98},"Q2: Is myeloablative conditioning always the most effective?","Not necessarily. It may provide better disease control for some patients, but it is not appropriate for everyone. The team assesses physical condition and treatment goals.",{"question":100,"answer":101},"Q3: Can older patients still undergo HSCT?","Some can. Reduced-intensity or non-myeloablative regimens may be considered for older patients or those with lower treatment tolerance to reduce risk.",{"question":103,"answer":104},"Q4: Can I request a different conditioning regimen?","You can discuss the characteristics and risks of the options with your doctor. The final regimen should be determined by the transplant team after medical assessment to safeguard safety and effectiveness.","More intensive conditioning is not necessarily better. Instead, it should be individualized based on the patient’s disease characteristics, physical status, and transplant goals.",{"key":107,"title":108,"html":109,"relatedQuestions":110,"hotSummary":123,"updatedAt":87},"choosing-the-right-hsct-conditionin","How Is the Right HSCT Conditioning Regimen Chosen?","\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Choosing a conditioning regimen before HSCT affects both transplant outcomes and treatment safety. There is no single regimen suitable for everyone. Doctors consider the disease, its status before transplantation, age, overall health and organ function. Rather than assuming that higher intensity is better, the aim is to balance disease control against treatment risk. An individualized plan helps improve the chances of a successful transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why must conditioning be individualized?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients often wonder why their pre-transplant drugs differ from those of other patients. HSCT is not a one-size-fits-all treatment. Patients have different diseases and levels of risk. Some have achieved good disease control before transplant; others still face a higher risk of relapse. Age and physical condition also influence the ability to tolerate intensive treatment. The goal is to control disease as far as possible while allowing the patient to complete transplantation safely and supporting donor-cell engraftment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What factors influence the choice?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The team first assesses disease status before transplant, which is closely related to prognosis. In some blood disorders, achieving complete remission (CR), especially a deep remission with negative measurable residual disease (MRD), may help reduce the risk of relapse afterward. If adequate remission has not been achieved despite active treatment, the team must evaluate the conditioning strategy more cautiously to optimize the outcome.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The team also evaluates the patient's physical condition. Younger, fitter patients can often tolerate more intensive conditioning. Older patients, or those with heart, lung, liver or kidney problems, require greater attention to safety. Previous treatment, transplant approach and donor factors can also influence the decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Is more intensive conditioning always better?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients and families may think that stronger drugs will remove disease more completely and improve transplant success. Higher intensity can indeed improve disease-cell elimination in some situations and may lower relapse risk for selected patients. At the same time, however, it can increase treatment toxicity, infection and transplant-related complications. Research and clinical experience indicate that intensity must be balanced against safety; simply increasing intensity does not necessarily improve overall survival. The most suitable regimen is the one that fits the patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How might the choice differ between patients?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">For younger, physically fit patients with high-risk disease, the team may consider more intensive conditioning to improve disease control. For older patients or those with limited treatment tolerance, RIC or NMA may be chosen to reduce treatment-related risks. Even when conditioning intensity is lower, the donor immune system may still contribute to disease control. The choice is therefore not simply between “strong” and “weak” treatment; it requires assessment of the whole clinical picture.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How should patients understand their regimen?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Rather than asking whether their regimen is the strongest, patients may find it more useful to ask whether it is right for them. A suitable plan considers whether it can control disease effectively, whether the body can tolerate it, whether it supports donor-cell engraftment and whether transplant-related risks can be minimized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients and families can ask why this particular regimen was chosen, what treatment goals it is intended to achieve, what risks may arise and what precautions are needed during treatment. Understanding the plan can make it easier to participate in the transplant process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Can the regimen change after it has been selected?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Sometimes. If a patient develops new health problems before transplantation, if infection or organ function changes, or if disease status changes, the transplant team may reassess the plan. Transplantation requires ongoing evaluation rather than a single unchanging decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Conditioning selection involves an overall assessment of disease status, age, physical condition, prior treatment and transplant goals. The strongest regimen is not necessarily the best; the objective is an appropriate balance between disease control and safety. A regimen suited to the individual is an important foundation for HSCT.\u003C\u002Fspan>\u003C\u002Fp>",[111,114,117,120],{"question":112,"answer":113},"Q1: Is a stronger regimen more likely to succeed?","No. Excessive intensity may increase treatment risks, while insufficient intensity may not achieve the desired disease control. The team balances efficacy and safety.",{"question":115,"answer":116},"Q2: Must I be in complete remission before transplantation?","Not in every situation. Good disease control before transplantation can improve outcomes for some patients, but patients with refractory disease may still need an individualized transplant strategy.",{"question":118,"answer":119},"Q3: Does older age rule out intensive conditioning?","Not necessarily. Age is only one consideration; physical condition, organ function and disease risk also matter.",{"question":121,"answer":122},"Q4: Can patients choose their own conditioning regimen?","Patients should discuss the options and their risks with the medical team, but the final plan must be based on the transplant team's clinical assessment.","More intensive conditioning is not necessarily better; rather, it is necessary to strike a balance between disease control efficacy and treatment safety.",{"key":125,"title":126,"html":127,"relatedQuestions":128,"hotSummary":141,"updatedAt":87},"hsct-conditioning-vs-chemotherapy","How Does HSCT Conditioning Differ from Standard Chemotherapy?","\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Conditioning before HSCT and chemotherapy used earlier in treatment can involve similar drugs, but they are not the same. Standard chemotherapy primarily aims to kill or control cancer cells and reduce disease burden. Conditioning also helps control disease, but it must suppress the recipient's immune system and prepare for donor stem-cell engraftment. It is a specialized stage of transplantation, designed according to the disease and transplant plan.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why are conditioning and chemotherapy often confused?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients preparing for HSCT may already have received several cycles of chemotherapy. When told they need conditioning, they naturally ask whether it is simply another cycle. Some drugs may be identical or similar, but the goals differ. Standard chemotherapy focuses mainly on the disease itself; conditioning prepares the body to receive donor cells and establish a new blood-forming system, while also helping control the disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What is standard chemotherapy?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Chemotherapy is an important treatment for blood disorders. It uses drugs to kill or inhibit rapidly dividing abnormal cells. In leukemia, lymphoma and other blood cancers, it may be used as initial treatment, to reduce disease burden, to achieve complete remission or to prepare for subsequent therapy. Its central aim is to reduce or eliminate disease cells as far as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What is HSCT conditioning?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Conditioning refers to chemotherapy, radiation therapy or immunosuppressive treatment given before donor stem-cell infusion. It has three main purposes: further reducing residual disease cells and post-transplant relapse risk; suppressing the recipient's immune system to reduce rejection of donor stem cells; and creating conditions that allow those donor cells to engraft. Conditioning therefore addresses both disease control and the transplantation process itself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What are the main differences?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">Different purposes\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Standard chemotherapy primarily controls disease by killing abnormal cells—for example, reducing leukemia cells and helping a patient reach remission. Conditioning also prepares for the establishment of a new blood-forming and immune system after donor cells are infused.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Different timing\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Standard chemotherapy is scheduled according to the disease-treatment plan and may involve multiple cycles. Conditioning is a defined phase immediately before HSCT; after it is completed, the patient proceeds to stem-cell infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Different treatment goals\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The main question for standard chemotherapy is how to control the disease. For conditioning, the team must also ask whether donor cells will engraft, whether the patient can tolerate treatment and what transplant-related risks may arise.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Intensity is chosen for the transplant\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Standard chemotherapy regimens are generally selected around disease treatment. Conditioning also depends on age, disease type, transplant method, donor characteristics and physical tolerance. Younger, fitter patients may receive more intensive conditioning; older or less fit patients may receive reduced-intensity regimens.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Is conditioning necessarily “stronger” than standard chemotherapy?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Not necessarily. Some conditioning regimens are highly intensive and remove disease cells more extensively, but others are intentionally reduced in intensity or non-myeloablative to lower treatment risks. The two cannot be ranked simply as stronger or weaker; the appropriate intensity depends on the individual plan.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why can't standard chemotherapy alone replace conditioning?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Families may ask why more treatment is needed when chemotherapy can already kill disease cells. The difference is that allogeneic transplantation also involves rebuilding the immune and blood-forming systems with cells from another person. Without appropriate preparation of the recipient's immune system, donor cells may be rejected and engraftment may be affected. Conditioning is therefore an essential part of the transplant process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What should patients watch for during conditioning?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Treatment-related symptoms may include nausea, vomiting, loss of appetite, mouth discomfort, fatigue and increased infection risk. Patients should promptly report physical changes, follow infection-prevention instructions and maintain adequate nutrition and rest. The clinical team can provide supportive treatment according to individual needs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Although standard chemotherapy and HSCT conditioning may use some of the same drugs, their purposes differ. Chemotherapy primarily controls disease; conditioning additionally prepares for donor-cell engraftment and reduces rejection risk. It is an indispensable, individualized part of HSCT.\u003C\u002Fspan>\u003C\u002Fp>",[129,132,135,138],{"question":130,"answer":131},"Q1: Is conditioning just chemotherapy?","Not entirely. It may include chemotherapy, but it also suppresses recipient immune responses and creates conditions for donor stem cells to engraft.",{"question":133,"answer":134},"Q2: Why is conditioning needed if I have already received chemotherapy?","The two serve different purposes. Chemotherapy mainly controls disease; conditioning also prepares the body for a new blood-forming system.",{"question":136,"answer":137},"Q3: Does conditioning cause more side effects than ordinary chemotherapy?","It depends on the regimen. Conditioning intensity and side effects vary. Doctors choose a suitable plan and provide supportive care according to the patient's condition.",{"question":139,"answer":140},"Q4: Does completing conditioning guarantee a successful transplant?","No. Conditioning is important, but outcomes also depend on disease status, donor compatibility and the management of infections and complications after transplantation.","Conditioning before HSCT and chemotherapy used earlier in treatment can involve similar drugs, but they are not the same.",{"key":143,"title":144,"html":145,"relatedQuestions":146,"hotSummary":159,"updatedAt":87},"hsct-conditioning-side-effects","What Side Effects Can Occur During HSCT Conditioning, and How Can They Be Relieved?","\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: Conditioning is a key stage of HSCT. Chemotherapy, radiation therapy or immunosuppressive treatment helps reduce disease burden, suppress immune rejection and prepare for donor-cell engraftment. Because these treatments can also affect healthy tissues and immune function, patients may experience nausea, vomiting, poor appetite, oral mucosal injury, increased infection risk and fatigue. Severity varies from person to person, and the clinical team can provide targeted supportive care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why does conditioning cause side effects?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients may worry that conditioning will make them very weak or that side effects indicate poor treatment results. Some discomfort is possible during conditioning. Although its purpose is to control disease, reduce rejection and help establish a new blood-forming system, conditioning drugs may also affect healthy cells, including those lining the digestive tract and those involved in blood-cell production in the bone marrow. Severity depends on age, overall health, the regimen and drug doses.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What are the common side effects?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp>\u003Cstrong style=\"font-size: 15px;\">Nausea, vomiting and loss of appetite\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Some chemotherapy drugs irritate the gastrointestinal tract, leading to stomach discomfort, nausea, vomiting or reduced appetite. Doctors may prescribe anti-nausea medicines and other supportive care. Under clinical guidance, patients may find easily digestible foods and smaller, more frequent meals helpful in maintaining nutritional intake.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Oral mucosal injury\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Some conditioning drugs affect the lining of the mouth, causing pain, ulcers or discomfort when swallowing. This can interfere with eating and increase infection risk. Oral care is therefore important. Follow the team's mouth-care instructions, and promptly report significant pain, ulcers or difficulty eating.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Low blood-cell counts and increased infection risk\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Conditioning affects the recipient's blood-forming system and may lower white blood cells, red blood cells or platelets. Low white blood-cell counts can reduce the body's ability to fight infection. During conditioning and transplantation, the team monitors blood counts and infection-related indicators and provides preventive or therapeutic measures as needed. Report fever, chills or other possible signs of infection promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Fatigue and weakness\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Some patients feel more tired than usual, with reduced energy or physical stamina. This may relate to medication, the demands of treatment or changes in blood counts. Rest according to your needs, avoid overexertion and remain appropriately active when your condition allows.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">Changes in organ function\u003C\u002Fstrong>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Different regimens may affect different organs. The team monitors important functions, including liver, kidney, heart and lung function, through regular testing and ongoing assessment so that problems can be identified and managed promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Do stronger side effects mean conditioning is working better?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. More noticeable side effects do not necessarily mean better disease control, and mild symptoms do not mean treatment is ineffective. Effectiveness must be evaluated using disease status, blood-forming recovery after transplant and subsequent examination results. Patients should not judge treatment results solely by how they feel.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How does the medical team relieve symptoms?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Supportive care is an important part of modern transplantation. The team may provide anti-nausea treatment, infection surveillance and prevention, transfusions or other support for low blood-cell counts, nutritional management, oral care and symptom-directed treatment. These measures help patients proceed through conditioning and transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What should patients do during conditioning?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Report changes promptly, especially fever, significant nausea or vomiting, worsening mouth pain or diarrhea. Pay close attention to personal hygiene and follow infection-prevention instructions because immune function may be reduced. Maintaining nutrition and emotional well-being can also help patients through this stage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Conditioning is an important foundation for HSCT, but it may affect healthy cells and immune function. Nausea, vomiting, mouth injury, infection risk and fatigue are among the effects that require attention. These reactions do not mean treatment has failed. With appropriate supportive care, close monitoring and cooperation with the team, most patients can complete conditioning and move on to the next transplant stage.\u003C\u002Fspan>\u003C\u002Fp>",[147,150,153,156],{"question":148,"answer":149},"Q1: Do side effects mean conditioning has failed?","No. Discomfort during conditioning does not establish treatment failure. Side effects mainly reflect treatment tolerance; transplant outcomes are assessed through disease control, blood-cell recovery and follow-up results.",{"question":151,"answer":152},"Q2: Does everyone develop severe side effects?","No. Severity differs according to the conditioning regimen, age, physical condition and underlying health problems.",{"question":154,"answer":155},"Q3: What should I do if I develop a fever during conditioning?","Tell the medical team promptly. Immune function may be suppressed, and clinicians need to investigate the cause and provide appropriate treatment.",{"question":157,"answer":158},"Q4: Can I continue eating normally during conditioning?","Many patients can still eat. If appetite loss, nausea or mouth problems develop, meals may need to be adjusted to the patient's condition. Nutritional support may be provided when needed.","Nausea, vomiting, mouth injury, infection risk and fatigue are among the effects that require attention. These reactions do not mean treatment has failed. ",{"key":161,"title":162,"html":163,"relatedQuestions":164,"hotSummary":177,"updatedAt":87},"best-timing-for-hsct","When Is the Best Time to Undergo HSCT?","\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Overview: HSCT is an important treatment for certain blood disorders, but not everyone needs immediate transplantation, and earlier is not always better. The right time depends on the disease type and risk, response to treatment, physical condition and donor readiness. For some high-risk diseases, transplantation at an appropriate time may reduce relapse risk and improve the opportunity for long-term disease control. For others whose disease is well controlled with other therapies, the need for transplant may require further assessment. Patients and the transplant team should make an individualized decision together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why does transplant timing matter?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">After diagnosis, patients may wonder whether they should undergo HSCT as soon as possible or why doctors recommend additional treatment first. Transplant timing is not simply a matter of sooner versus later. HSCT is complex and requires reasonably stable disease status, sufficient physical tolerance, a suitable donor and acceptable transplant-related risks. Proceeding immediately when disease is poorly controlled or the body cannot tolerate transplantation may affect the outcome. The goal is to identify a window when treatment can be delivered safely and effectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>When should HSCT be considered?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Indications and timing vary among blood disorders. In some hematologic malignancies, including acute leukemia and myelodysplastic syndromes, doctors assess disease risk to determine whether transplantation is needed. HSCT may offer an important chance for long-term control in high-risk or relapse-prone disease. For some lower-risk patients whose disease can be controlled for a long time with medication or other treatments, doctors may reassess the need for transplant according to disease progression. The diagnosis alone does not determine the decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why do many patients undergo HSCT after achieving remission?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients often ask why transplantation cannot happen immediately after diagnosis. Disease status before HSCT affects outcomes. For some blood disorders, doctors aim for good disease control, such as complete remission, before transplantation. Lower disease burden at that point may reduce relapse risk afterward. In acute leukemia in particular, the depth of remission is an important planning factor. Some patients therefore receive induction or consolidation treatment first to bring the disease under the best possible control before transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Should everyone undergo HSCT as early as possible?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. If disease risk is high, relapse is likely and the patient's condition permits, doctors may recommend proceeding promptly during an appropriate treatment window. But older patients, people with limited physical tolerance, severe infections or organ-function problems, and those whose disease can currently be managed in other ways may need stabilization or a different treatment strategy first. Timing must balance the need for disease control with treatment safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What influences transplant timing?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Disease factors include diagnosis, risk classification, relapse status and depth of response to treatment. Patient factors include overall health, major organ function, infection status and ability to tolerate conditioning and transplantation. Donor readiness also matters: allogeneic HSCT may require a donor search, HLA matching and donor health assessment. All of these influence the final schedule.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What happens if the ideal transplant window is missed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Patients may fear that any delay means losing their opportunity. The consequences depend on the individual situation. In some high-risk diseases, relapse or progression can make later treatment more difficult and affect transplant outcomes. Teams therefore plan ahead to use an appropriate window. On the other hand, transplanting too early when disease control is inadequate or physical readiness is poor may increase risk. The “best time” is not a fixed date; it is when disease status, physical condition and treatment arrangements are appropriately aligned.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How can patients and families prepare?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">While waiting, follow the treatment plan to control disease as well as possible. Maintain nutrition, take steps to prevent infection and pay attention to changes in health. Learning about conditioning, donor selection and post-transplant management can also help families understand the process and reduce uncertainty and anxiety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cstrong style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 8px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">HSCT timing influences treatment outcomes, but immediate or earlier transplantation is not always better. The team considers disease type and risk, treatment response, physical condition and donor readiness. For patients who need transplantation, using the right treatment window and preparing carefully are important to both safety and effectiveness.\u003C\u002Fspan>\u003C\u002Fp>",[165,168,171,174],{"question":166,"answer":167},"Q1: Is it always better to have HSCT as early as possible?","No. Timing must reflect disease status, physical condition and donor readiness.",{"question":169,"answer":170},"Q2: Must I wait until my disease is in complete remission?","It depends on the disease and the individual. Better disease control can improve outcomes for some patients, but high-risk or refractory disease may require a different individualized plan.",{"question":172,"answer":173},"Q3: If I cannot undergo HSCT right now, have I lost my chance?","Not necessarily. Some patients first need other treatment to improve disease control or physical condition, after which transplant eligibility can be reassessed. Plans may change as the patient's condition evolves.",{"question":175,"answer":176},"Q4: Can transplantation begin immediately once a donor is found?","Not always. The schedule also depends on current disease status, physical condition and completion of transplant preparations.","The right time depends on the disease type and risk, response to treatment, physical condition and donor readiness.",[],{"author":67,"reviewedBy":67,"lastReviewed":67,"datePublished":67,"citations":180,"disclaimer":67},[],false,1792294305653]